BridgeMD
Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic malignancy
EU CTIS ID: 2024-512969-14-01
What this study is testing
To evaluate the effect of allogeneic FMT compared with no treatment on graft-versus-host disease-free, relapse-free survival (GRFS) at one year post-transplant in patients treated with myeloablative conditioning (MAC) allo-HSCT for haematological malignancy
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients who underwent allo-HSCT for a controlled haematological malignancy
- Patients aged ≥ 18 years old
- Patients affiliated with a social security organization
- Patients who had signed informed consent
- With myelo-ablative type conditioning
- With an allogeneic peripheral stem cell transplant, regardless of the type of donor (except cord blood)
You likely can't join if
- Patient with tumor progression status at the time of allo-HSCT
- History of another progressive cancer or one occurring in the previous 3 years (excluding basal cell carcinoma)
- Faecal incontinence
- Allograft of HSC from bone marrow
- Patient suffering from a serious and uncontrolled concomitant condition (severe cardiac, renal, hepatic or respiratory failure, serious sepsis)
- Patient under guardianship, curatorship or safeguard of justice
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.